Nanosynex
Antimicrobial Susceptibility Test
StartupNanosynex is a Tel Aviv-Yafo-based startup in the Health Tech & Life Sciences sector, established in 2017. Antimicrobial Susceptibility Test. The company has raised a total of $6.34M across 7 funding rounds, currently at the Seed stage. Nanosynex was founded by Diane Abensur and Michelle Heymann. Key investors include Undisclosed Investor(s). The company has 1-10 employees. Core technologies: Biologicals, Platforms & Interfaces, Software.
With $6.34M in total funding, Nanosynex is a Seed-stage company operating in Health Tech & Life Sciences. The company follows a B2B business model. Product stage: R&D. The company holds 1 patent.
- StageSeed
- ProductR&D
- ModelB2B
- Employees1-10
- HQTel Aviv-Yafo
- DistrictCenter District
- Last Round$40K
- Undisclosed Investor(s)
Diane AbensurCo-founder & CEOMichelle HeymannCo-founder & VP Marketing & Operations
6 articles covered by sources including m-jpost-com.cdn.ampproject.org,
www.360dx.com,
forbes.co.il,
en.globes.co.il,
www.israel21c.org.
What does Nanosynex do?
Nanosynex is developing solutions designed to improve testing quality and reduce healthcare costs by accelerating diagnostic processes. Nanosynex is focused on the development and commercialization of an innovative antimicrobial susceptibility test (AST). The technology is based on a purely phenotypic approach and uses a microfluidic disposable test cartridge platform and method that optimizes bacterial growth. The Nanosynex solution comprises a disposable test platform, hardware, and analysis software. The product will allow laboratories to perform and provide results for same-day antimicrobial susceptibility tests, enabling doctors to create targeted, personalized antibiotic prescriptions for their patients. The companys technology stems from research discoveries made in the lab of Professor Shulamit Levenberg, dean of the Faculty of Biomedical Engineering at the Technion.
How much funding has Nanosynex raised?
Nanosynex has raised $6.34M in total funding across 7 rounds. The company is currently at the Seed stage. Key investors include Undisclosed Investor(s).
Who founded Nanosynex?
Nanosynex was founded in 2017 by Diane Abensur (Co-founder & CEO), Michelle Heymann (Co-founder & VP Marketing & Operations).
What sector is Nanosynex in?
Nanosynex operates in Health Tech & Life Sciences, Digital Healthcare, Digital Medical Diagnostics, Medical Decision Support, with core technologies in Biologicals, Platforms & Interfaces, Software. Target customers: Healthcare & Life Sciences, Healthcare, Laboratories, Providers.
Where is Nanosynex located?
Nanosynex is based in Hovevei Tsiyon Street 22, Tel Aviv-Yafo, Israel, Center District.